Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2019-08-15 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - SUBMISSION OF CLINICAL TRIAL APPLICATION FOR INVESTIGATIONAL FIRST-IN-CLASS NEW DRUG ALMB-0166 IN AUSTRALIA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the Board of Directors of CSPC Pharmaceutical Group Limited regarding the submission of a clinical trial application for a new investigational drug. It is an announcement of a corporate development related to clinical trials and drug development, not a financial report, regulatory filing, or management report. The document is short (2726 characters) and does not contain financial data, audit information, or voting results. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category that does not fit other specific categories, which is Regulatory Filings (RNS).
2019-08-15 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the unaudited interim results for the six months ended 30 June 2019. It does not contain the actual interim financial report or detailed financial data, but merely announces the upcoming board meeting and the agenda item. The document length is only 1292 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, such announcements about the timing of report approval or board meetings are best classified as Regulatory Filings (RNS) because they do not contain substantive financial data or the report itself. Therefore, the appropriate classification is RNS with high confidence.
2019-08-07 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2019
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, including share options, warrants, convertibles, and other share-related transactions for the month ended 31/7/2019. The document includes confirmations by a director regarding compliance with listing rules and legal requirements related to securities issued during the month. There are no financial statements, earnings data, or management discussion of financial results. The content focuses on share capital changes and confirmations related to securities issuance, which aligns with announcements regarding share capital changes rather than full financial reports or earnings releases. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length is substantial (13,749 characters), indicating it is the report itself, not just an announcement of a report publication or a certification letter, so it is not RPA or RNS.
2019-08-01 English
VOLUNTARY ANNOUNCEMENT - NEW TARGET ANTI-TUMOR DRUG "SYHA1807" WAS GRANTED CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the approval of a new anti-tumor drug "SYHA1807" for clinical trials by the National Medical Products Administration of China. It is a short announcement (2307 characters) and does not contain any financial data, detailed financial performance, or regulatory filings related to financial results. It is not an annual report, interim report, earnings release, or any detailed financial or management report. It is also not related to board changes, voting results, or share transactions. The announcement is about a clinical trial approval, which is a regulatory update but not a legal proceeding or merger activity. Given the short length and nature of the content, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-07-29 English
INSIDE INFORMATION - ANNOUNCEMENT ON THE INDICATIVE RESULTS FOR THE HALF YEAR ENDED 30 JUNE 2019 OF CSPC INNOVATION PHARMACEUTICAL CO., LTD.*
Regulatory Filings Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the indicative results for the half year ended 30 June 2019 of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. It explicitly states that the financial data is preliminary, unaudited, and based on estimates, and that the detailed and audited results will be disclosed in the company's interim report for 2019. The document is relatively short (5177 characters) and serves to inform investors of preliminary financial performance rather than providing a full financial report. It is an inside information announcement with indicative results, not the actual interim report itself. Therefore, it fits best as a Regulatory Filing (RNS) since it is a regulatory announcement that does not contain substantive financial statements or detailed analysis required for an Interim/Quarterly Report (IR).
2019-07-12 English
CONTINUING CONNECTED TRANSACTIONS - RENEWAL OF STEAM SUPPLY AGREEMENT
Regulatory Filings Classification · 95% confidence The document is an announcement from CSPC Pharmaceutical Group Limited regarding the renewal of a steam supply agreement with Hebei Hongyuan, which is a connected person under the Listing Rules. The announcement details the terms of the new agreement, historical transaction amounts, proposed annual caps, reasons and benefits for entering into the agreement, and the implications under the Hong Kong Stock Exchange Listing Rules Chapter 14A concerning continuing connected transactions. The document is structured as a formal announcement with no financial statements or detailed financial analysis, but rather focuses on disclosure of a continuing connected transaction and compliance with listing rules. It is not an annual report, interim report, earnings release, or any form of financial statement. It is also not a management or board change announcement, nor a legal proceeding or merger announcement. The content fits the category of a regulatory announcement related to compliance and disclosure of connected transactions under listing rules. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), indicating it is not a brief report publication announcement but a full announcement. Confidence is high given the clear nature of the content and its alignment with typical regulatory announcements for connected transactions under Hong Kong Listing Rules.
2019-07-12 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.